Related references
Note: Only part of the references are listed.Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate
Courtney S. Watts et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2016)
Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions
R. W. F. van Leeuwen et al.
ANNALS OF ONCOLOGY (2015)
Recommendations to improve the usability of drug-drug interaction clinical decision support alerts
Thomas H. Payne et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2015)
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
Hyoung Jin Kang et al.
LANCET ONCOLOGY (2015)
Use of Complementary and Alternative Medicine in Children with Cancer: A Study at a Swiss University Hospital
Tatjana Magi et al.
PLOS ONE (2015)
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective
Roelof W. F. van Leeuwen et al.
LANCET ONCOLOGY (2014)
Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients
M. Angeles Fernandez de Palencia Espinosa et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2014)
Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs
R. W. F. van Leeuwen et al.
BRITISH JOURNAL OF CANCER (2013)
Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study
Molouk Hadjibabaie et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Tendon Injury and Fluoroquinolone Use: A Systematic Review
Anne L. Stephenson et al.
DRUG SAFETY (2013)
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
R. W. F. van Leeuwen et al.
ANNALS OF ONCOLOGY (2011)
Risk of Azole-Enhanced Vincristine Neurotoxicity in Pediatric Patients With Hematological Malignancies: Old Problem - New Dilemma
Zoe Dorothea Pana et al.
PEDIATRIC BLOOD & CANCER (2011)
Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
L. Lee Dupuis et al.
PEDIATRIC BLOOD & CANCER (2011)
Aprepitant: drug-drug interactions in perspective
M. S. Aapro et al.
ANNALS OF ONCOLOGY (2010)
Benefits of the Intermittent Use of 6-Mercaptopurine and Methotrexate in Maintenance Treatment for Low-Risk Acute Lymphoblastic Leukemia in Children: Randomized Trial From the Brazilian Childhood Cooperative Group Protocol ALL-99
Silvia R. Brandalise et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs
Marsha L. Voll et al.
PHARMACY WORLD & SCIENCE (2010)
Potential drug interactions and duplicate prescriptions among cancer patients
Rachel P. Riechelmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Drug therapy: Drug-induced prolongation of the QT interval
DM Roden
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Developmental pharmacology - Drug disposition, action, and therapy in infants and children
GL Kearns et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clinical-pharmacological strategies to assess drug interaction potential during drug development
J Kuhlmann et al.
DRUG SAFETY (2001)
Fever and neutropenia in pediatric hematopoietic stem cell transplant patients
CA Mullen et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
